Serplulimab plus chemotherapy for early-relapsed colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with colorectal cancer that came back within 1 year after surgery (stage IV with cancer spread)
- You completed standard post-surgery chemotherapy (XELOX or FOLFOX regimen)
- Your tumor tissue has been tested and shows pMMR, MSS, or MSI-L status (not MSI-H)
- You have at least one measurable tumor spot on imaging scans
- Your overall health is good enough for treatment (ECOG performance 0–1)
- Your blood counts, liver, kidney, and thyroid function are adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for advanced low rectal cancer. You'll receive a combination of chemotherapy, immunotherapy, and radiation before surgery, which may help shrink the tumor and make surgery easier.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of three drugs—chemotherapy plus two targeted therapies—as a first treatment for colorectal cancer that cannot be surgically removed. The goal is to shrink tumors enough to allow surgery later, potentially improving outcomes.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.